Tin tức & Cập nhật

Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).

The direct oral anticoagulants (DOACs) apixaban and rivaroxaban trump warfarin for the treatment of venous thromboembolism (VTE) in a retrospective observational analysis comprising real-world VTE patients from Finland, Norway, and Sweden.

Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024. 

Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.

Findings from the ongoing POLAC project demonstrate that treatment with the pangenotypic regimen comprising glecaprevir/pibrentasvir (GLE/PIB) for 8 weeks is highly effective against chronic hepatitis C virus (HCV) infection in children and adolescents. This regimen also showed a good safety profile.

Avelumab immunotherapy may perform poorly in advanced endometrial cancer (EC) patients with TP53 mutation but has positive effects in those with mutations of PTEN and ARID1A, suggest the results of the MITO END-3 trial.

Use of efgartigimod, a first-in-class investigational antibody fragment targeting the neonatal Fc receptor (FCRN), demonstrates both efficacy and safety in patients with refractory, treatment-resistant generalized myasthenia gravis (MG), as shown in a study presented at EAN 2024.